Overwater Ventures, GV, and Khosla Ventures invest in a rigorous clinical approach that raises throughput for fertility clinics, expands access, and empowers women to plan on their own terms
Overture Life announced a $20.6 million strategic round, bringing its total funding to $57 million from leading industry investors, to support additional clinical research and product development designed to make IVF affordable to more people. The company is also announcing its newly achieved CLIA (Clinical Laboratory Improvement Amendments) license in the United States to meet federal clinical laboratory standards for m|z, its AI-powered, non-invasive metabolomic test for embryo selection. These latest milestones reinforce Overture’s commitment to demonstrating scientific rigor, securing regulatory support, and prioritizing patient safety. They also pave the way for the launch of DaVitri, an advanced embryology platform that automates egg freezing (vitrification) and embryo warming under reproducible, data-driven protocols.
Health Technology Insights: Paige and NHS Wales Launch AI PanCancer Pilot at Betsi Cadwaladr
For too long, IVF has been inaccessible for too many people, with inefficiencies driving up costs. Since 2017, Overture has modernized the core technology involved in IVF through proprietary software, robotics, microfluidics and rigorous scientific validation, documented in peer-reviewed publications, scientific presentations, and, most importantly, two healthy, live births resulting from the use of its technology.
Its newest platform, DaVitri, addresses essential lab steps that historically rely on manual precision. By standardizing these procedures with precise timing and controlled cryoprotectant exposure, DaVitri has demonstrated improved oocyte survival rates in early clinical evaluations, potentially reducing repeated IVF cycles that can drain resources and emotional energy. In addition, its streamlined, gentler freezing process helps clinics maintain consistent lab results, allowing embryologists to handle more cycles without compromising quality.
“This new funding allows us to accelerate our expansion of IVF capabilities and demonstrates the value of operating within a CLIA-licensed laboratory environment, highlighting not only our technological leadership but also our commitment to the highest standards of clinical validation,” said Hans Gangeskar, CEO of Overture Life. “DaVitri has already shown potential to significantly increase clinical throughput while ensuring reproducibility in critical freezing and warming processes, allowing embryologists to prioritize personalized patient care. Our approach is rigorous and evidence-based because we understand how deeply personal this journey is for families.”
Health Technology Insights: Health Net, Partners Team Up to Improve Care in Sacramento
“Automation and standardization in the embryology lab is an exciting step towards optimizing efficiency and efficacy in IVF. It allows us to deliver consistent and excellent care, while still giving us the flexibility to fine-tune protocols for our patients,” said Serena H. Chen, MD, a Reproductive Endocrinologist at CCRM Fertility of NJ. “We’re very excited about the potential to serve more patients by increasing lab capacity without sacrificing quality.”
This strategic round, supported by Overwater Ventures, GV (formerly Google Ventures), and Khosla Ventures, reflects a deep conviction in Overture’s science-led mission: to expand fertility access by making IVF labs more reproducible, efficient, and ultimately less cost-intensive.
“Fertility intersects healthcare, economics, and the most personal of human wishes,” said Kristina Simmons, Founder and Managing Partner at Overwater Ventures. “Women have long faced irreversible biological timelines, and by making egg freezing cheaper, easier, and more clinically effective and predictable, it allows women and families to regain choice and opportunity. Overture’s platform provides a precise alternative that can run more cycles successfully, enabling women to freeze their eggs or pursue IVF on their own terms and timelines. By fitting the embryology protocols into a compact, desk-sized system, Overture is reinventing egg freezing and IVF for a better patient experience and strong, clinically reproducible outcomes with proven science.”
Health Technology Insights: Socially Determined, Acentra Partner to Advance Population Health
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
